The IAS Industry Liaison Forum promotes and facilitates the full contribution of the biomedical industry to the global HIV response by catalyzing multi-stakeholder dialogue, engagement and action to address barriers along the HIV prevention, diagnosis and care continuum.
MEMBERSHIP

The ILF consists of members who come from a diversity of backgrounds, expertise and affiliations, both from industry and non-industry organizations.

**Industry Members**

- biopharmaceutical companies (originator and generic)
- diagnostics companies
- health-related product manufacturers (e.g., condom companies)
- other health-technology companies

**Non-Industry Members**

- the IAS
- regulatory and normative agencies
- procurement and implementing organizations
- governmental and inter-governmental organizations
- civil society and communities affected by HIV/AIDS

Appendix 1: Evolution of ILF Industry Members
informal review informed by consultations with a broad range of industry actors

multi-year focus on a restricted set of topics

notably paediatric ARVs and WHO prequalification.

Appendix 2: Evolution of ILF topics
THE ILF TODAY

A strategic review led by independent consultants in 2020 highlighted that, overall, the ILF is appreciated by its members, who see it as unique due to its:

- **focus on advancing the global HIV response**, particularly in low-income countries;
- **neutrality and convening power** – from its affiliation with the IAS;
- **composition** – which brings together a diversity of industry and non-industry stakeholders (spanning a range of backgrounds, expertise and affiliations) who seldom have a chance to meet and exchange openly;
- **way of regarding, treating and respecting ILF industry members as partners** (rather than ‘adversaries’) in the HIV response, and giving them a voice in shaping ILF priorities; and
- **rules of engagement** that simultaneously create a collegial, safe, constructive space for dialogue and engagement, and ensure compliance with ethical rules.
MOVING FORWARD

The strategic review concluded that:

• there is value in fostering connection and dialogue within the ILF membership;
• the ILF can usefully draw attention to HIV issues and possible solutions by making its perspectives known; and
• with the ILF’s composition having broadened (in particular to include a wider variety of companies) and member interests having evolved over time, there is an appetite amongst members to refresh and reenergize the ILF.

Through this 2020-2023 Strategic Plan, the ILF wishes to further build on its unique attributes to revitalize its value to ILF members, and strengthen its contribution to the HIV response.
2020 - 2023
STRATEGIC FRAMEWORK

Values
The ILF is a results-orientated partnership underpinned by the values of collaboration, openness and transparency.

Foundation
The work of the ILF, an equal and inclusive multi-stakeholder partnership, is driven by an unrelenting focus on quality and reputation towards advancing the HIV response.
The ILF will continue to act as a cross-stakeholder, neutral, ‘safe-space’ platform that actively expands and engages its membership base in order to foster connections, dialogue and action.
1. **Increased membership engagement** through an established calendar of up to six annual in-person convenings* and teleconferences that are well-planned, relevant, goal-oriented and participative.

2. **Strategic membership growth** in alignment with the ILF Mission.

3. **Membership of the ILF expanded** to enable members to participate in both the IAS cure and vaccine sub-advisory groups.

* COVID-19 may impact the potential of in-person convenings. Alternative virtual formats will be utilized.
The ILF members will **agree and advance specific topics** that address barriers along the HIV prevention, diagnosis and care continuum.
1. An agreed and clearly defined, collaborative and transparent **topic selection process**.

2. Annual **collaboration by the ILF** on:
   - One cross-cutting topic; and
   - One topic specific to an ILF industry*

Each topic must have a fixed timeline, to include a clear exit strategy, and pre-established metrics for success.

* ILF industries include pharmaceuticals (discovery), pharmaceuticals (generic), diagnostics.
The ILF will **develop and publish perspectives, where relevant, to advance the global HIV response.**
1. Documented broadly-agreed **perspectives** or **recommendations** on each topic.

2. Relevant perspectives/recommendations **shared publicly** via appropriate channels.
STRATEGY IMPLEMENTATION

1. Establish a predictable and balanced yearly schedule of compelling ILF activities
2. Agree annual topics and success metrics by Quarter 4 the previous year
3. Expand membership by 2-3 Industry Members per year in alignment with the mission of the ILF
4. Document and publish 1-2 relevant perspectives annually
5. Implement feedback loop to continuously review and improve ILF processes

...refresh & re-energize the ILF
WHAT DOES SUCCESS LOOK LIKE?

A committed, engaged and expanded membership base… working together in a safe, neutral space to advance shared topics in HIV prevention, diagnosis and cure… in order to advance the global HIV response through ongoing awareness raising and the publication of agreed perspectives.
“The ILF's capacity to bring various stakeholders around the table for open discussion - this is unique.” – ILF member
The ILF STRATEGIC PLAN 2020 - 2023 was developed through a consultative process led by independent consultants. Inputs included a review of historic ILF documents; structured interviews with a broadly-representative cross-section of ILF members (industry and non-industry), past Co-Chairs, the IAS President; and discussions with IAS senior management.
Evolution of ILF Industry Members

Members by type

Number of industry members (companies)

Discovery pharma
Generic pharma
Diagnostics
Condom

Year
## Evolution of ILF Topics

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-trial care</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PrEP research and implementation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R</td>
</tr>
<tr>
<td>Research priorities for women and children</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>M</td>
</tr>
<tr>
<td>- HIV prevention options for women</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>R</td>
</tr>
<tr>
<td>- PMTCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>M</td>
</tr>
<tr>
<td>- Paediatric ARVs (incl. GAP-I)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regulatory affairs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnostics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key populations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GIPA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-infections</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacovigilance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV cure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV vaccines</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ILF scope</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**LEGEND:**

- **Topics planned in:**
  - 3-year ILF strategic plan
  - ILF annual workplan only

- **Topics addressed in:**
  - R: Report
  - B: Webinar
  - M: Meeting
  - S: Survey

- P: Proposal
- MMR: Meeting, MMR
- MMB: Meeting, MMR, B
- MRR: Meeting, R, R
- MR: Meeting, R
- MM: Meeting, M
- MMR: Meeting, MMR
- MBB: Meeting, MMR, B
- MRR: Meeting, R, R